Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · USM201561018 US Manufacturing
Open in API
Filings indexed 379 across all filing types
Latest filing 2026-05-28 Regulatory Filings
Country US United States of America
Listing US ENLV

About Enlivex Therapeutics Ltd.

https://www.enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage company developing macrophage reprogramming immunotherapy. Its primary focus is the development of Allocetra™, a universal, off-the-shelf cell therapy designed to rebalance immune hyper-responses. The therapy aims to modulate macrophages as a therapeutic strategy against inflammatory diseases. Enlivex is evaluating Allocetra™ for multiple indications, including acute inflammatory conditions like sepsis and chronic inflammatory diseases such as osteoarthritis. The product offers flexible administration options, including systemic intravenous infusion and targeted local injections, and has been administered in clinical trials to over 250 patients with no reported drug-related serious adverse events.

Recent filings

Filing Released Lang Actions
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 92% confidence The document is an SEC Form 6-K “Report of Foreign Private Issuer,” providing a press release as an exhibit and filed under the Exchange Act. It does not contain full financial statements or substantive analysis itself but is a regulatory submission for a foreign issuer. This matches the fallback “Regulatory Filings” category.
2026-05-28 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 98% confidence The document is a Form 6-K “Report of Foreign Private Issuer” furnished under the Securities Exchange Act. It provides a press release as Exhibit 99.1. It does not contain substantive financial statements or serve as an earnings release, proxy, or annual/interim report itself, but rather is a regulatory report of a foreign issuer. Therefore it falls under the Regulatory Filings category (RNS).
2026-05-27 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 90% confidence The document is a Form 6-K “Report of Foreign Private Issuer” filed under the Securities Exchange Act, consisting of a press release as Exhibit 99.1. It does not itself provide full financial statements or constitute an annual/interim report, nor does it announce board changes, dividends, or other specific events covered by more precise categories. Hence it falls under the catch-all “Regulatory Filings” category (RNS).
2026-05-18 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 91% confidence The document is a Form 6-K “Report of Foreign Private Issuer” filed with the SEC, providing a Nasdaq notice and furnishing a press release as Exhibit 99.1. It does not contain actual financial statements or detailed management discussion, but is a regulatory update. Under the taxonomy, such general regulatory announcements and filings (including 6-Ks) are classified as Regulatory Filings (RNS).
2026-05-15 English
6-K - Enlivex Ltd. (0001596812) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It announces the receipt of Clinical Trial Application approval and includes a press release as an exhibit. The document is short (1767 characters) and primarily serves as an announcement rather than a full report containing financial data or detailed analysis. It does not contain financial statements or substantive financial data. Therefore, it fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and filings that do not fit other specific categories.
2026-04-21 English
6-K - Enlivex Ltd. (0001596812) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It announces a press release about the launch of a tokenized representation of the company's shares on a trading platform. The document is short (1810 characters) and primarily serves as a regulatory announcement rather than a full financial report or detailed filing. It does not contain financial statements or detailed analysis, nor is it an annual or quarterly report. It is not a certification or officer attestation. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-04-08 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.